Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial

BACKGROUND: Patients with permanent atrial fibrillation have poor outcomes, exercise capacity, and quality of life even on optimal anticoagulation. Based on mechanistic and observational data, we tested whether the mineralocorticoid receptor antagonist spironolactone can improve exercise capacity, E...

Full description

Saved in:
Bibliographic Details
Published in:J Am Heart Assoc
Main Authors: Shantsila, Eduard, Shahid, Farhan, Sun, Yongzhong, Deeks, Jonathan, Calvert, Melanie, Fisher, James P., Kirchhof, Paulus, Gill, Paramjit S., Lip, Gregory Y. H.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2020
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7726985/
https://ncbi.nlm.nih.gov/pubmed/32909497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.016239
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items